Chiusura precedente | 78,73 |
Aperto | 80,56 |
Denaro | 0,00 x 0 |
Lettera | 0,00 x 0 |
Min-Max giorno | 80,56 - 80,56 |
Intervallo di 52 settimane | 80,56 - 80,56 |
Volume | |
Media Volume | N/D |
Capitalizzazione | 14,672B |
Beta (5 anni mensile) | 0,41 |
Rapporto PE (ttm) | 374,70 |
EPS (ttm) | 0,22 |
Prossima data utili | 26 lug 2022 - 01 ago 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”), of the important December 22, 2021 lead plaintiff deadline. SO WHAT: If you purchased BioMarin securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen
NEW YORK, Dec. 19, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-08254, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired BioMarin securities bet
NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between January 13, 2020 and September 3, 2021, inclusive (the “Class Period”), of the important December 22, 2021 lead plaintiff deadline. SO WHAT: If you purchased BioMarin securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen